ValuEngine Upgrades Mylan (MYL) to "Buy"

Thursday, 07 Dec, 2017

Its the same as in 2017Q1.

Tekla Capital Management Llc increased Mylan N.V. (MYL) stake by 3.4% reported in 2017Q2 SEC filing. Louisiana State Employees Retirement System now owns 29,300 shares of the company's stock valued at $1,117,000 after buying an additional 1,300 shares during the period. Vantage Investment Limited Company stated it has 712 shares or 0.01% of all its holdings.

The focus shifting on performance of the Mylan N.V. (NASDAQ:MYL) that has shown a discernible change in trend levels over the path of recent market activity. Also published the news titled: "Mylan shares soar on Amazon reports, FDA approvals" on December 01, 2017. Cowen restated a "hold" rating and set a $30.00 target price (down from $43.00) on shares of Mylan in a research report on Wednesday, August 9th. Gulf Interest Financial Bank (Uk) Limited holds 0.08% or 139,930 shares. BMO Capital Markets maintained the shares of MYL in report on Monday, October 30 with "Buy" rating. They now have a $46.0 PT on the firm. The target price by UBS would suggest a potential upside of 25.10 % from the company's close price. The other 13, though not evenly; between analysts who think you should buy Mylan N.V. versus those who think you should sell it. Out of 2 Wall Street analysts rating MarineMax, 1 give it "Buy", 0 "Sell" rating, while 1 recommend "Hold". Therefore 63% are positive. Mylan has a 12-month low of $33.60 and a 12-month high of $50.40. Mylan Inc. had 54 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has "Hold" rating by RBC Capital Markets given on Friday, August 4. The United Kingdom-based Gulf Bancorporation (Uk) Ltd has invested 0.08% in Mylan N.V. (NASDAQ:MYL). This has been released in an analyst report on Thursday, 5 October. The stock of Mylan N.V. (NASDAQ:MYL) earned "Equal-Weight" rating by Morgan Stanley on Monday, August 7. The stock has "Hold" rating by Argus Research on Tuesday, August 22. Deutsche Bank maintained it with "Buy" rating and $65 target in Tuesday, July 28 report. UBS maintained Mylan N.V. (NASDAQ:MYL) rating on Monday, December 4. Mizuho maintained it with "Buy" rating and $47 target in Friday, November 18 report. The company was maintained on Friday, July 14 by RBC Capital Markets. The Average Volume of the company is 6.15 Million, while the Volume of the company in the last trading session was 6.06 Billion.

In the past 52 weeks the company's stock price has moved within the range of $29.39 to $45.87. Of those insider trades, 0 shares of Mylan N.V. were purchased and 0 shares were sold. It has underperformed by 24.43% the S&P500.

Mylan N.V., together with its subsidiaries, develops, licenses, makes, markets, and distributes generic, brand name, and over-the-counter products worldwide. During the same quarter in the prior year, the business earned $1.38 earnings per share. It also reduced Yelp Inc (NYSE:YELP) stake by 1.66 million shares and now owns 1.00M shares. FMR LLC now owns 813,267 shares of the company's stock worth $31,572,000 after buying an additional 134,258 shares during the period.

Analysts await Mylan N.V. (NASDAQ:MYL) to report earnings on March, 7. Menora Mivtachim Holdings Ltd who had been investing in Mylan N V for a number of months, seems to be less bullish one the $19.77 billion market cap company. The firm operates through three divisions: North America, Europe, and Rest of World. It has a 19.56 P/E ratio. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.